Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 12
2004 11
2005 7
2006 9
2007 4
2008 13
2009 20
2010 19
2011 14
2012 18
2013 15
2014 20
2015 22
2016 14
2017 17
2018 16
2019 15
2020 18
2021 24
2022 20
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Results by year

Filters applied: . Clear all
Page 1
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. Reig M, et al. Among authors: bruix j. J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19. J Hepatol. 2022. PMID: 34801630 Free PMC article. Review.
Hepatocellular carcinoma.
Forner A, Reig M, Bruix J. Forner A, et al. Among authors: bruix j. Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5. Lancet. 2018. PMID: 29307467 Free article. Review.
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Banales JM, et al. Among authors: bruix j. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32606456 Free PMC article. Review.
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Llovet JM, et al. Among authors: bruix j. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857. N Engl J Med. 2008. PMID: 18650514 Free article. Clinical Trial.
Breakthroughs in Hepatocellular Carcinoma Therapies.
Singal AG, Kudo M, Bruix J. Singal AG, et al. Among authors: bruix j. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2135-2149. doi: 10.1016/j.cgh.2023.01.039. Epub 2023 Feb 20. Clin Gastroenterol Hepatol. 2023. PMID: 36813012 Review.
Management of hepatocellular carcinoma: an update.
Bruix J, Sherman M; American Association for the Study of Liver Diseases. Bruix J, et al. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. Hepatology. 2011. PMID: 21374666 Free PMC article. No abstract available.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Kelley RK, et al. Among authors: bruix j. J Clin Oncol. 2021 Sep 20;39(27):2991-3001. doi: 10.1200/JCO.20.03555. Epub 2021 Jul 22. J Clin Oncol. 2021. PMID: 34292792 Free PMC article. Clinical Trial.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Bruix J, et al. Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines.
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C. Ayuso C, et al. Among authors: bruix j. Eur J Radiol. 2018 Apr;101:72-81. doi: 10.1016/j.ejrad.2018.01.025. Epub 2018 Jan 31. Eur J Radiol. 2018. PMID: 29571804 Review.
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Orci LA, et al. Among authors: bruix j. Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10. doi: 10.1016/j.cgh.2021.05.002. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 33965578 Free article. Review.
279 results